Effects of zishentongluo in patients with early-stage diabetic nephropathy.
Effects of zishentongluo in patients with early-stage diabetic nephropathy.
复制标题
DOI：
10.1142/s0192415x13500249
复制
发表时间：
2013-04
期刊：
影响因子：
--
通讯作者：
Jianwei Ma;Limei Xu;Jing Dong;Hanlin Wei;Y. Zhi;Xinyin Ma;Wenlong Zhang
中科院分区：
文献类型：
--
作者：
Jianwei Ma;Limei Xu;Jing Dong;Hanlin Wei;Y. Zhi;Xinyin Ma;Wenlong Zhang
本研究旨在探讨滋肾通络（ZSTL）治疗糖尿病肾病（DN）的疗效及其作用机制。45名DN患者随机接受ZSTL （n = 25）或苯那普利（n = 20），一种血管紧张素转换酶抑制剂，为期12周。常规生化试验测定空腹血糖（FBG）、糖化血红蛋白（HbA1c）、血清肌酐（SCr）、内源性肌酐清除率（Ccr）、总胆固醇（TC）和甘油三酯（TG）水平。用放射免疫法测定尿白蛋白排泄率（UAER）、内皮素1 （ET-1）和心房利钠肽（ANP）水平，用酶联免疫吸附法检测血管内皮生长因子（VEGF）。主要终点是HbA1c从基线到治疗后的变化。次要终点是FBG、TC、TG、UAER、SCr、Ccr、VI-C、ANP、ET-1和VEGF从基线到治疗后的变化。ZSTL在改善主要（如HbA1c）和次要（如FBG、TC、TG、UAER、SCr、ANP、ET-1和VEGF）结局方面明显优于苯那普利（p < 0.05）。这些发现表明，ZSTL在改善早期DN患者的代谢和肾功能方面优于苯那普利，部分原因是通过改变ANP、ET-1和VEGF。
The purpose of this study was to assess the efficacy of zishentongluo (ZSTL) for the treatment of diabetic nephropathy (DN) and its related mechanisms. Forty-five patients with DN were randomized to receive either ZSTL (n = 25) or benazepril (n = 20), an angiotensin converting enzyme inhibitor, for 12 weeks. Conventional biochemical tests were performed to determine fasting blood glucose (FBG), glycated hemoglobin (HbA1c), serum creatinine (SCr), endogenous creatinine clearance rate (Ccr), total cholesterol (TC), and triglyceride (TG) levels. The urinary albumin excretion rate (UAER), and endothelin 1 (ET-1), and atrial natriuretic peptide (ANP) levels were determined with a radioimmunoassay, and vascular endothelial growth factor (VEGF) was detected using an enzyme-linked immunosorbent assay. The primary endpoint was change from the baseline to post-treatment in HbA1c. Secondary endpoints were change from baseline to post-treatment in FBG, TC, TG, UAER, SCr, Ccr, VI-C, ANP, ET-1, and VEGF. ZSTL was significantly more effective at improving the primary (i.e., HbA1c) and secondary (i.e., FBG, TC, TG, UAER, SCr, ANP, ET-1, and VEGF) outcomes than benazepril (p < 0.05). These findings suggest that ZSTL is superior to benazepril at improving the metabolic and renal functioning in patients with early-stage DN, in part, by modifying ANP, ET-1, and VEGF.